Men1: A Potential Drug Target and Biomarker (G4221)

Target Name: MEN1

NCBI ID: G4221

MEN1

Men1: A Potential Drug Target and Biomarker

Men1 (MEAI) is a gene that encodes a protein known as megalin. Megalin is a transmembrane protein that is involved in many different processes in the body, including cell adhesion, migration, and invasion. It is a key regulator of the neural tube development and the formation of the nervous system.

Men1 has also been shown to be involved in the development and progression of many diseases, including cancer. It has been linked to the development of various types of cancer, including neurobladder cancer, ovarian cancer, and prostate cancer.

One of the main reasons for the potential clinical significance of Men1 is its involvement in cancer development. By targeting Men1, researchers hope to be able to develop new treatments for these deadly diseases.

In addition to its potential as a drug target, Men1 is also a potential biomarker. Its expression has been shown to be elevated in a variety of cancer types, including neurobladder cancer, ovarian cancer, and prostate cancer. This suggests that Men1 may be a useful diagnostic or predictive marker for these diseases.

Furthermore, Men1 has also been shown to play a role in the development and progression of other diseases. For example, it has been linked to the development of age-related cognitive decline and Alzheimer's disease.

Overall, Men1 is a protein that is of great interest to researchers because of its involvement in so many different processes in the body. Its potential as a drug target and biomarker make it an attractive target for further study.

Protein Name: Menin 1

Functions: Essential component of a MLL/SET1 histone methyltransferase (HMT) complex, a complex that specifically methylates 'Lys-4' of histone H3 (H3K4). Functions as a transcriptional regulator. Binds to the TERT promoter and represses telomerase expression. Plays a role in TGFB1-mediated inhibition of cell-proliferation, possibly regulating SMAD3 transcriptional activity. Represses JUND-mediated transcriptional activation on AP1 sites, as well as that mediated by NFKB subunit RELA. Positively regulates HOXC8 and HOXC6 gene expression. May be involved in normal hematopoiesis through the activation of HOXA9 expression (By similarity). May be involved in DNA repair

The "MEN1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MEN1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets